Clinical Trials Logo
  1. Home
  2. Restenosis
  3. NCT03146221
  4. Details
NCT03146221 Clinical Trial

Search for Restenosis Markers in Lower Limb Arteritis

Restenosis Clinical Trial

— FEMIA  

Official title:
Search for Restenosis Markers in Lower Limb Arteritis

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT03146221
Other study ID # PI2016_843_0004
Secondary ID
Status Withdrawn
Phase N/A
First received May 2, 2017
Last updated July 19, 2017
Start date June 20, 2017
Est. completion date June 20, 2020

Study information
Verified date July 2017
Source Centre Hospitalier Universitaire, Amiens
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The initial hypothesis of this work is that the genesis and the evolution of the atheromatous plaque are partly controlled at the molecular level and in particular by the microRNAs through their role as regulator of the genes.

The study of the tissue and serum profile over time of specific microRNAs involved in the regulation of atheromatous plaque correlated with clinical data and restenosis imaging will allow to define biological markers of restenosis in the patient with an arteritis of the lower limbs .

This study is a pioneer in the field and it would be imprudent to conclude that a biomarker would be used clinically at the end of this work alone. Nevertheless this study will make a major advance in this topic, in vivo intervention studies with inhibition or over-expression of microRNA will obviously be necessary to confirm the use of these as biomarkers of arteritis of the lower limbs.

Regular assay of reliable biomarkers in arterial patients will ultimately suggest early management to best adapt surgical and medical treatment.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date June 20, 2020
Est. primary completion date June 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Any person to be surgically treated for arteritis on the femoropoplitetic stage,

- affiliated to a social security scheme,

- informed of the study and not opposed to it.

Exclusion Criteria:

- Any person taken in charge for an arteritis on the femoro-popliteal floor refusing to participate in the study,

- or not being able to express its consent.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• To look for serum microRNA profiles associated with restenosis
To look for serum microRNA profiles associated with restenosis

Locations
Country Name City State
France CHU Amiens Picardie Amiens Picardie

Sponsors (1)
Lead Sponsor Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Study of the tissue and serum profile of microRNAs by quantification by real-time PCR 3 years
See also
  Status Clinical Trial Phase
Completed NCT01970579 - Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter Phase 3
Completed NCT01861860 - OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA N/A
Completed NCT01722877 - JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions N/A
Recruiting NCT00774917 - Numen Stent Assessment Using OCT Technique in a Single Center Study Phase 2/Phase 3
Completed NCT00493597 - Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of In-stent Restenosis
Completed NCT00647504 - Prospective Clinical Observational Registry Including Consecutive Patients With In-stent Restenosis or Stent Thrombosis N/A
Not yet recruiting NCT01476020 - Is There A LIfe for Drug Eluting Stent (DES) After Discontinuation of Clopidogrel Phase 3
Terminated NCT00780156 - The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel N/A
Terminated NCT00712257 - Study to Evaluate the Safety and Performance of Spectranetics Laser w/Adjunct PTA and Gore Viabahn Endoprosthesis for Treatment of SFA Instent Restenosis N/A
Completed NCT01065532 - SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study N/A
Recruiting NCT03613337 - Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention
Completed NCT03332264 - Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions N/A
Completed NCT02063672 - Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis N/A
Recruiting NCT05451368 - Neointimal Features in Patients With Restenosis of Calcified Lesions
Completed NCT02649946 - Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft N/A
Completed NCT01632371 - Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4 Phase 4
Completed NCT00798954 - Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial Phase 4
Completed NCT02790606 - Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA) N/A
Completed NCT01405248 - Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting Phase 3
Completed NCT00987324 - Efficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent Restenosis Phase 4